Skip to main content
Premium Trial:

Request an Annual Quote

Horizon Discovery, CareDx Ink OEM Agreement

NEW YORK (GenomeWeb) — Horizon Discovery Group said today that it has entered into an original equipment manufacturer agreement with CareDx.

Under the agreement, Horizon will supply cell-free DNA-based molecular reference standards for inclusion in CareDx's cfDNA testing workflows for the monitoring of transplanted organ rejection. Financial details of the agreement were not disclosed.

The agreement is an extension of a previously announced collaboration for the development of cell-free reference standards to support proficiency testing of CareDx's solid organ transplant injury monitoring test, AlloSure. The companies expect to forge future similar agreements, Horizon said.

"The inclusion of Horizon's reference standards as a routine tool used by CareDx demonstrates that Horizon is becoming a trusted provider of controls in the liquid biopsy space, and that they are equally valuable for applications beyond oncology," Horizon CEO Darrin Disley said in a statement. "This agreement further validates Horizon's strategy of entering into early development programmes with assay service providers and kit vendors, and working closely with them to forge long-term relationships and establish ongoing OEM-based revenue streams."

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.